Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PRIMIS)

Conditions

Diseases of the Digestive System - Liver

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

Ages
18 years - 75 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Gilead Sciences, Inc.
Start Date
02/19/2020
End Date
08/31/2023

For more information about this study, contact:

Suzie Christopher

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Marina Silveira, MD
Associate Professor of Medicine (Digestive Diseases)

Sub-Investigator

David N. Assis, MD

Last Updated
07/15/2021
Study HIC
#2000025197

Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PRIMIS)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigator

Contact Information